

# IN 2022, DAMON RUNYON SCIENTISTS PUSHED THE BOUNDARIES OF WHAT IS POSSIBLE IN SCIENCE TO UNCOVER NEW WAYS TO DETECT, PREVENT, AND TREAT ALL FORMS OF CANCER.

## THIS YEAR ALONE, DAMON RUNYON SCIENTISTS:

- **Developed an implantable biosensor** for early detection of ovarian cancer.
- Launched a clinical trial for **the first genetically targeted therapy for cancer prevention**, a drug that treats a pre-cancerous blood condition called clonal hematopoiesis.
- **Engineered a new kind of CAR T immune cell** for the treatment of solid tumors and demonstrated its effectiveness in mice.
- Elucidated **the neural pathways that cause the sensation of nausea**, paving the way for better strategies to combat this common serious side effect of cancer treatment.

---

## AWARDS AND HONORS

Damon Runyon alumni elected to the National Academy of Sciences (the science “Hall of Fame”): **William M. Clemons, Jr., PhD; Gordon J. Freeman, PhD; Linda C. Hsieh-Wilson, PhD; Erik M. Jorgensen, PhD; Alex L. Kolodkin, PhD; Michael J. Lichten, PhD; Joseph D. Mougous, PhD; Julie A. Segre, PhD.**

Damon Runyon alumni elected to the American Academy of Arts & Sciences, one of the oldest honorary societies in the country: **Arshad B. Desai, PhD; Gordon J. Freeman, PhD; Z. Josh Huang, PhD; Matthew L. Meyerson, MD, PhD.**

Former Damon Runyon Fellow **Daniel J. Blair, PhD**, was named a 2022 STAT Wunderkind for his groundbreaking development of a “Lego-like” building kit for the automated synthesis of new molecules that can be the basis of cancer therapies.

Former Damon Runyon Fellow **Pardis C. Sabeti, MD, DPhil**, received a 2022 Time100 Impact Award for her critical role in sequencing viral genomes, including that of SARS-CoV-2.

Former Damon Runyon Clinical Investigator **Eli M. Van Allen, MD**, was awarded the FNIH Trailblazer Prize for his many contributions to the development of precision cancer medicine, particularly with the use of computational biology.

# DAMON RUNYON CANCER RESEARCH FOUNDATION

Funding brave and bold.

## OUR MISSION

At the Damon Runyon Cancer Research Foundation, we fund high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave, and bold enough to go where others haven't.

## RESEARCH PROGRAMS

- We currently fund **187 scientists** across **54 academic research institutions**.
- In fiscal year 2022, we awarded nearly **\$17.2 million** in new grants to **58 exceptional scientists**, and provided an additional **\$1.6 million** in stipend increases, extension funding for pandemic-related research delays, and other support.

## FINANCIAL INFORMATION



**TOTAL REVENUE:**  
**\$22 MILLION**

- Investment Return **56.6%**
- Contributions **36.2%**
- Misc. Income **4.0%**
- Bequests & Trusts **2.6%**
- Damon Runyon Broadway Tickets **0.6%**



**TOTAL EXPENSES:**  
**\$22 MILLION**

- Award Programs **86.7%**
- Fundraising **9.6%**
- General Administration **3.7%**

## 100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.

[DAMONRUNYON.ORG](https://damonrunyon.org) | 1.877.7CANCER

